News

Dr. Roland W. Bürli Joins Scenic Biotech as CSO for Innovations

Dr. Roland W. Bürli Joins Scenic Biotech as CSO for Innovations

Scenic Biotech Welcomes Dr. Roland W. Bürli as Chief Scientific Officer

Scenic Biotech has appointed Dr. Roland W. Bürli as its new Chief Scientific Officer (CSO). Dr. Bürli's proven expertise, honed over 25 years in drug development, positions him to lead Scenic Biotech's innovative pipeline focused on modifier therapies.

Advancing Therapeutics Through Expert Leadership

With a rich background in the biotech sector, Dr. Bürli is set to accelerate the development of first-in-class therapies targeting neurodegenerative and metabolic diseases. His extensive experience includes key roles at numerous pharmaceutical companies, where he successfully guided programs from conception through clinical trials.

Contribution and Expertise

Oscar Izeboud, CEO of Scenic Biotech, expressed enthusiasm about Dr. Bürli's appointment, emphasizing how his extensive experience in drug discovery will help enhance the company's advancement efforts. Dr. Bürli's strategic vision is set to strengthen Scenic Biotech's scientific strategy and expedite the clinical evaluation of its lead programs.

An Innovative Approach to Therapy

Dr. Bürli is excited to join Scenic Biotech at a pivotal moment in the company's growth. He believes the company's revolutionary work in modifier therapies will significantly affect how severe disorders are treated. His commitment to leveraging the Cell-Seq platform to uncover new therapeutic options demonstrates a forward-thinking attitude towards medical challenges.

Background and Experience of Dr. Bürli

Prior to joining Scenic Biotech, Dr. Bürli played a crucial role at Codify Therapeutics, where he established its discovery platform soon after the company's inception. He also served as the VP of Drug Discovery at Cerevance, leading a dynamic team and contributing to the successful advancement of several promising programs. His accomplishments include developing the small-molecule candidate CVN293, which completed Phase 1 trials.

A Proven Track Record

Throughout his career, Dr. Bürli has held significant scientific roles at leading organizations, including AstraZeneca and Amgen. His contributions have significantly impacted various therapeutic areas like CNS disorders and inflammation. With more than 135 publications and patents to his name, Dr. Bürli is well-positioned to enrich Scenic Biotech's innovative trajectory.

Scenic Biotech's Vision for the Future

Scenic Biotech is not just making strides in drug development; it's paving the way for a revolutionary approach to treating genetic disorders. The company's focus on modifier therapy stands out as it doesn't merely target disease-causing mutations. Instead, it aims to enhance health by modulating other genes that can mitigate disease impact.

Commitment to Research and Clinical Applications

Scenic Biotech's robust pipeline, derived from the proprietary Cell-Seq platform, consists of wholly-owned programs complemented by collaborations with major pharmaceutical entities. By aiming to unlock new genetic pathways, the company strives to develop a portfolio of therapies that genuinely address patient needs.

Contact Scenic Biotech For More Information

For further insights into the groundbreaking work at Scenic Biotech or to learn more about Dr. Bürli's initiatives, you can reach out directly:

Oscar Izeboud, PhD, CEO
Phone: +31 20 7059 990
Email: info@scenicbiotech.com

Frequently Asked Questions

Who is Dr. Roland W. Bürli?

Dr. Bürli is the newly appointed Chief Scientific Officer of Scenic Biotech, bringing over 25 years of drug development experience.

What is Scenic Biotech's focus?

Scenic Biotech specializes in developing modifier therapies to treat genetic disorders, emphasizing a novel approach to healthcare.

Why is Dr. Bürli's appointment significant?

His vast experience in drug development and leadership within biotech companies will strengthen Scenic Biotech's research and therapeutic strategies.

What are modifier therapies?

Modifier therapies aim to alter gene expressions to improve health outcomes rather than directly targeting disease-causing mutations.

How can I get in touch with Scenic Biotech?

You can contact them directly through their CEO, Oscar Izeboud, via email at info@scenicbiotech.com or by phone at +31 20 7059 990.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Zunyi’s History Tour Carries China’s Story Overseas

Updated Category News Views 75

China’s national story does not travel overseas by accident; it gets carried by visitors, monuments, rail lines, rivers and carefully chosen questions. The Zunyi News and Media Center report follows Tayyab, a Pakistani PhD student in aerospace engineering at Peking University, as he heads from Beijing to Zunyi, Guizhou, carrying a copy of Edgar Snow’s Red Star Over...

Continue Reading
Marelli’s Two Awards Put Practical Auto Tech in Focus

Updated Category News Views 22

Two trophies in Novi do not fill an order book, but Marelli’s latest pair says something useful about where automotive suppliers are trying to earn their keep. The company collected a 2026 Automotive News PACE Award for HorizonView and a PACE Pilot Award for Affordable 5G RedCap at the November 17 ceremony. One is already deployed in production; the other is a...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 109

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
Leqembi’s Real-World Data Gives BioArctic More Weight

Updated Category News Views 79

A Harder Look at Treatment Staying Power Alzheimer’s drug data rarely arrive without a thicket of caveats, and that is exactly why this Leqembi update deserves a calm read rather than a victory lap. BioArctic’s partner Eisai presented a three-year real-world analysis at CTAD 2026 covering 560 early Alzheimer’s patients across 13 U.S. sites. The headline is striking:...

Continue Reading
Perform.AI Tests Whether Stores Can Sell to Agents

Updated Category News Views 39

Shopping bots are about to become one more fussy customer standing in the aisle, except this one reads machine-facing files, rejects broken checkout steps, and does not care how pretty the homepage looks. Perform.AI has launched a free UCP and ACP Readiness Checker aimed at online retailers that need to know whether AI agents can find products, purchase them, and follow...

Continue Reading
Villa Group’s Punta Mita Bet Adds 305 Luxury Resort Keys

Updated Category News Views 102

A 12.6-acre slice of Riviera Nayarit coastline is about to get a very expensive makeover, assuming The Villa Group can turn a handsome plan into a functioning resort without the usual development headaches. The company says it has acquired a beachfront parcel in Litibú and intends to build Villa La Valencia Punta Mita, a 305-accommodation luxury property aimed squarely...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 320

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
Pacific Surfliner Faces Thanksgiving Capacity Test

Updated Category News Views 35

Thanksgiving traffic on Southern California freeways is its own yearly punishment, and the Pacific Surfliner is making a sensible pitch: leave the car parked and let the coast roll past the window. For travelers, that can be a real relief. For anyone watching public transportation, this is also a useful little stress test of whether a busy state-supported rail corridor...

Continue Reading
DocLinq Takes Aim at Care Gaps Between Office Visits

Updated Category News Views 0

Healthcare's most expensive loose ends often pile up after the appointment ends. DocLinq, launched from Columbia, Maryland, is taking a run at that awkward stretch between office visits, where records sit in separate systems, chronic-care follow-up gets uneven, and patients are expected to remember far more than any human reasonably can. This is not a story about AI...

Continue Reading
New Flight Charters Puts a Cap on Winter Surprises

Updated Category News Views 255

Ice on a wing is routine; ice on an invoice is where charter customers start muttering. New Flight Charters says it will again absorb de-icing and hangar charges this winter, up to $2,500 per trip, marking the seventh consecutive season for the program. In a business where the headline quote can look tidy and the final bill can arrive wearing muddy boots, that is a...

Continue Reading

Top 5 Most Recently Viewed Articles

Unisys to Engage with Investors at Sidoti Conference Soon

Updated Category News Views 137

Unisys to Connect with Investors at Sidoti Conference Soon Unisys (NYSE: UIS), a leader in technology solutions, is preparing to participate in the upcoming Sidoti Small-Cap Conference. This virtual event allows investors to hear directly from the company's executives, offering valuable insights. Meet with Unisys Executives The conference provides a fantastic chance for...

Continue Reading
VedaBio Welcomes Randy Rasmussen to Board of Directors

Updated Category News Views 341

VedaBio, a key player in biotechnology, took a bold step back in 2024 by appointing Randy Rasmussen, Ph.D., to its Board of Directors. This wasn’t just a casual hire; it’s an infusion of over 30 years of expertise into their operation. With Dr. Rasmussen at the helm, the chatter on the trading floor picked up—everyone was eyeing how this could reshape VedaBio's...

Continue Reading
Acuity Brands Sets Date for Fiscal 2025 First-Quarter Release

Updated Category News Views 99

Acuity Brands to Release Fiscal 2025 First-Quarter Results Acuity Brands, Inc. (NYSE: AYI) has announced an important date for investors and stakeholders. The company will release its fiscal 2025 first-quarter results on a Thursday morning, signaling its ongoing commitment to transparency and communication with its shareholders. Details of the Upcoming Announcement The...

Continue Reading
NV5 Global Successfully Secures Approval for Merger Deal

Updated Category News Views 166

NV5 Global Secures Stockholder Approval for Merger with Acuren Recently, NV5 Global, Inc. (NASDAQ: NVEE), a prominent provider of technology-driven engineering, testing, inspection, and consulting services, announced a major milestone. A significant majority of its stockholders voted in favor of the merger with Acuren Corporation, showcasing strong support for this...

Continue Reading
Why MacBook Users Shouldn't Worry About EU's USB-C Directive

Updated Category News Views 395

Understanding the New EU USB-C Directive The recent implementation of the EU’s USB-C directive has stirred discussions among electronics users, particularly MacBook owners. Effective from 2025, this directive mandates that mobile devices, including smartphones and tablets, must incorporate a USB-C port for charging. The significance of this directive extends beyond just...

Continue Reading